Gamida Cell (NASDAQ: GMDA) is one of 114 publicly-traded companies in the “Biological products, except diagnostic” industry, but how does it compare to its peers? We will compare Gamida Cell to similar businesses based on the strength of its earnings, risk, analyst recommendations, dividends, valuation, institutional ownership and profitability.
This is a summary of recent ratings and recommmendations for Gamida Cell and its peers, as provided by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|Gamida Cell Competitors||809||2698||5966||251||2.58|
Insider and Institutional Ownership
1.7% of Gamida Cell shares are owned by institutional investors. Comparatively, 48.7% of shares of all “Biological products, except diagnostic” companies are owned by institutional investors. 15.6% of shares of all “Biological products, except diagnostic” companies are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.
This table compares Gamida Cell and its peers’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|Gamida Cell Competitors||-5,041.11%||-62.49%||-26.17%|
Earnings & Valuation
This table compares Gamida Cell and its peers gross revenue, earnings per share and valuation.
|Gross Revenue||Net Income||Price/Earnings Ratio|
|Gamida Cell||N/A||-$52.93 million||-1.09|
|Gamida Cell Competitors||$934.72 million||$204.36 million||-1.34|
Gamida Cell’s peers have higher revenue and earnings than Gamida Cell. Gamida Cell is trading at a higher price-to-earnings ratio than its peers, indicating that it is currently more expensive than other companies in its industry.
Gamida Cell beats its peers on 6 of the 11 factors compared.
About Gamida Cell
Gamida Cell Ltd., a clinical stage biopharmaceutical company, focuses on developing cell therapies to cure cancer, and rare and serious hematologic diseases in the United States, the European Union, and internationally. The company's lead product candidate is NiCord, a nicotinamide (NAM)-expanded cord blood cell therapy that is in Phase III studies in a patients with high-risk blood cancers, as well as in Phase I/II studies in patients with severe aplastic anemia. It is also developing NAM-NK, an innate immunotherapy, which is in Phase I studies for the treatment of relapsed or refractory non-Hodgkin lymphoma and multiple myeloma. The company was founded in 1998 and is headquartered in Jerusalem, Israel.
Receive News & Ratings for Gamida Cell Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gamida Cell and related companies with MarketBeat.com's FREE daily email newsletter.